Genomic and Proteomic Profiling Targets Influenced Treatment in Metastatic Breast Cancer

Withdrawn before enrolling · Not applicable

Conditions studied: Metastatic Breast Cancer, Breast Tumor, Advanced Gynecologic Cancer

In brief

The primary objective is to examine the impact on progression-free survival of targeted therapy for breast cancer suggested by proteomic and genomic profiling.

Key facts

Study ID

NCT02470819

Run by

Avera McKennan Hospital & University Health Center

People needed

0

Starts

2014-03-01

Expected to finish

2018-10-30

Last updated by the study team

2018-11-07

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Life expectancy of >3 months
• Diagnosis of metastatic breast cancer or an advanced gynecological malignancy with measurable disease
• Age greater than or equal to 18 years
• ECOG performance status of 0-1
• Able to undergo two biopsies to obtain tissue with first biopsy required and second biopsy optional
• Have failed or unable to tolerate previous treatment regimen
• Adequate organ and bone marrow function as defined by ANC ≥ 1.5 x 109/L; Hgb 9 g/dL; platelets greater than 100 x 109/L; creatinine ≤ 1.5 mg/dL; bilirubin ≤ 2.5 x ULN; AST and ALT ≤ 2.5 x ULN (or ≤ 5 x ULN if due to underlying liver metastases); INR ≤ 1.5 x ULN (except in the case of anticoagulation therapy)

You may not qualify if…

• Metastatic lesions that are not accessible to biopsy
• Symptomatic CNS metastasis
• Previous history of another malignancy within 5 years of study entry
• Uncontrolled concurrent illness
• Known HIV, HBB, and/or HCV infection
• Pregnant or breast feeding or childbearing potential and not using adequate birth control

Where it is running

• Avera Cancer Institute — Sioux Falls, South Dakota, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.